TY - JOUR
T1 - Clinical research in endometrial cancer
T2 - consensus recommendations from the Gynecologic Cancer InterGroup
AU - Creutzberg, Carien L.
AU - Kim, Jae Weon
AU - participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research
AU - Eminowicz, Gemma
AU - Allanson, Emma
AU - Eberst, Lauriane
AU - Kim, Se Ik
AU - Nout, Remi A.
AU - Park, Jeong Yeol
AU - Lorusso, Domenica
AU - Mileshkin, Linda
AU - Ottevanger, Petronella B.
AU - Brand, Alison
AU - Mezzanzanica, Delia
AU - Oza, Amit
AU - Gebski, Val
AU - Pothuri, Bhavana
AU - Batley, Tania
AU - Gordon, Carol
AU - Mitra, Tina
AU - White, Helen
AU - Howitt, Brooke
AU - Matias-Guiu, Xavier
AU - Ray-Coquard, Isabelle
AU - Gaffney, David
AU - Small, William
AU - Miller, Austin
AU - Concin, Nicole
AU - Powell, Matthew A.
AU - Stuart, Gavin
AU - Bookman, Michael A.
AU - Barretina-Ginesta, Pilar
AU - Bennett, Katherine
AU - Berek, Jonathan
AU - Berger, Regina
AU - Bjørge, Line
AU - Boere, Ingrid
AU - Brennan, Donal
AU - Bruchim, Ilan
AU - Chang, Ting Chang
AU - Chavez Blanco, Adriana
AU - Chen, Xiaojun
AU - Colombo, Nicoletta
AU - Crosbie, Emma
AU - Denys, Hannelore
AU - Duska, Linda
AU - Fruehauf, Filip
AU - Gomez Garcia, Eva Maria
AU - van Gorp, Toon
AU - Grimm, Christoph
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/9
Y1 - 2024/9
N2 - The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2–3, 2023. The aims were to develop consensus statements for future trials in endometrial cancer to achieve harmonisation on design elements, select important questions, and identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and finalisation of 18 statements within four topic groups, addressing adjuvant treatment in high-risk disease; treatment for metastatic and recurrent disease; trial designs for rare endometrial cancer subgroups and special circumstances; and specific methodology and adaptation for trials in low-resource settings. In addition, eight areas of unmet need were identified. This was the first GCIG Consensus Conference to include patient advocates and an expert on inclusion, diversity, equity, and access to take part in all aspects of the process and output. Four early-career investigators were also selected for participation, ensuring that they represented different GCIG member groups and regions. Unanimous consensus was obtained for 16 of the 18 statements, with 97% concordance for the remaining two. Using the described methodology from previous Ovarian Cancer Consensus Conferences, this conference did not require even one minority statement. The high acceptance rate following active involvement in the preparation, discussion, and refinement of the statements by all representatives confirmed the consensus progress within a global academic setting, and the expectation that the ECCC will lead to greater harmonisation, actualisation, inclusion, and resolution of unmet needs in clinical research for individuals living with and beyond endometrial cancer worldwide.
AB - The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2–3, 2023. The aims were to develop consensus statements for future trials in endometrial cancer to achieve harmonisation on design elements, select important questions, and identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and finalisation of 18 statements within four topic groups, addressing adjuvant treatment in high-risk disease; treatment for metastatic and recurrent disease; trial designs for rare endometrial cancer subgroups and special circumstances; and specific methodology and adaptation for trials in low-resource settings. In addition, eight areas of unmet need were identified. This was the first GCIG Consensus Conference to include patient advocates and an expert on inclusion, diversity, equity, and access to take part in all aspects of the process and output. Four early-career investigators were also selected for participation, ensuring that they represented different GCIG member groups and regions. Unanimous consensus was obtained for 16 of the 18 statements, with 97% concordance for the remaining two. Using the described methodology from previous Ovarian Cancer Consensus Conferences, this conference did not require even one minority statement. The high acceptance rate following active involvement in the preparation, discussion, and refinement of the statements by all representatives confirmed the consensus progress within a global academic setting, and the expectation that the ECCC will lead to greater harmonisation, actualisation, inclusion, and resolution of unmet needs in clinical research for individuals living with and beyond endometrial cancer worldwide.
UR - https://www.scopus.com/pages/publications/85202452114
U2 - 10.1016/S1470-2045(24)00192-X
DO - 10.1016/S1470-2045(24)00192-X
M3 - Review article
C2 - 39214113
AN - SCOPUS:85202452114
SN - 1470-2045
VL - 25
SP - e420-e431
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 9
ER -
SDG 3 Good Health and Well-being